GENSCRIPT BIO's stock plummeted 5.26% during intraday trading on Monday, extending recent declines as investors continued to take profits following the digestion of a key catalyst.

The decline represents a continuation of profit-taking after the ASCO annual meeting catalyst. GenScript's associate company Legend Biotech had presented multiple research results at the ASCO conference, including Phase 1 clinical data for a DLL3-targeting CAR-T therapy for relapsed or refractory small cell lung cancer, alongside new CARVYKTI data. This news had previously driven the stock higher, but subsequent sessions have seen sustained selling pressure as the positive catalyst was fully priced in.

Adding to the downward pressure, Hong Kong Stock Connect channels recorded consecutive large-scale net outflows in recent sessions, raising concerns that institutional investors leveraged the ASCO rally to reduce their positions. At the sector level, the broader Life Sciences Tools and Services space also weakened, amplifying the drag on GenScript's stock performance.